# Akso Health Group share price today (Akso Health Group, AHG)

> Akso Health Group's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. AHG · Healthcare · Medical Distribution · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/ahg

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $1.21 (−25.3% in a year)
- Revenue (Mar 2026): $6.8 M (−12.9% on a year ago)
- Profit (Mar 2026), incl. one-off: −$17.4 M (one-off item, see below)
- Operating margin: −37.5% (+5.6 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Akso Health Group share price today? Akso Health Group's share price was $1.21 at the close on 3 November 2026. That is 19.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between $1 and $3, and at that close it sat 26% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 24 weeks running. Over the last 1 year the share price moved −30% while the S&P 500 moved +21%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 22 May 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Akso Health Group pay? Akso Health Group pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Akso Health Group on? Akso Health Group is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Akso Health Group profitable? Akso Health Group posted a net loss of $17.4 M in the Mar 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY26 year was a loss of $18.7 M. That loss is 254.9% of the quarter's revenue. The same quarter a year earlier lost $6.1 M. 11 of the last 12 reported quarters were loss-making. Read this profit with care: at −$17.4 M it is bigger than the quarter's whole revenue of $6.8 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −37.5% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does Akso Health Group make, and is it growing? Akso Health Group reported $6.8 M of revenue in the Mar 2026 quarter, −12.9% on the same quarter a year earlier. Over 4 years it has grown 23.2% a year on average. The last full year, FY26, came in at $13.8 M. FY26 revenue was $13.8 M, −6.4% on the year before. Recent pace: the last four quarters grew +269.8% on average, against 23.2% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +83.4%, against +278.2% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does Akso Health Group keep? Akso Health Group's operating margin was −37.5% in the Mar 2026 quarter, 5.6 percentage points higher than the same quarter a year ago. Over the last four quarters it has moved +378.1 percentage points. Across 5 years it has been between −357.8% and −26.5%. The latest quarter is within that range. Why the margin moved: operating margin changed +378.1 percentage points on the year while gross margin changed −14.8 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Akso Health Group's profit turning into cash? Akso Health Group's cash-flow history is too short to judge how much of its profit turns into cash. In FY26 its operations used $12.8 M of cash, against −$18.7 M of profit. After $2.0 K of spending on assets, free cash was −$12.8 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Akso Health Group's cash go? Akso Health Group does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $156 K on assets over the last 2 years. Averaged over those years that is 0.6% of FY26 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $156 K over the last 2 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Akso Health Group's P/E ratio, and how does it compare with its own history? Akso Health Group has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Akso Health Group at 74.9× its FY26 revenue of $13.8 M. The P/E comes back here once profit turns positive. ## Is the Akso Health Group business getting better or worse? Akso Health Group's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Akso Health Group earn on its capital? Akso Health Group earned a ROE of −10% in FY26. That is up from a low of −137% in FY22. Its return on capital used (ROIC) is left out: on sales this small it reads −1,536%, a number that says nothing useful about the business. It comes from a −135.3% net margin and 0.07× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −135.3% net margin × 0.07× asset turnover × 1.05× leverage (assets divided by equity) ≈ −9.9% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does Akso Health Group have too much debt? Akso Health Group has total debt of $2.4 M against shareholder equity of $181 M as of Mar 2026, so its debt is 0.01× its equity, which is very little. Year by year, that ratio went from 0.58 in FY21 to 0.01 in FY26. So the returns on this page come from the business, not from borrowed money. ## What is the Akso Health Group shareholding pattern? We have no ownership or short-position figures for Akso Health Group, so this section says so rather than fill the gap. At normal trading volumes, closing those positions would take about 0.3 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. ## How far is Akso Health Group from balance-sheet trouble? For Akso Health Group, the Z-score is 56.98. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 56.98 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Akso Health Group rank in its industry? 35.2 out of 100, rank 5 of 8 in Medical Distribution, with 51% of the evidence available. Akso Health Group scores 35.2 out of 100 against the 8 companies it is compared with in Medical Distribution, ranking 5. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 17.2 + 4.8 + 9.5 + 3.7 = 35.2. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Akso Health Group compared with? Akso Health Group ranks 5 of 8 Medical Distribution companies on the 4-Factor Sector Score, with 35.2 out of 100. 1. [McKesson Corporation](https://www.sectoralpha.in/us/stocks/mck) MCK · leader · Most evidence points up · 85% evidence 79.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.7/35 · Revenue 8.8% · Profit 58.1% · Operating margin change 0 points · 95% evidence Capital efficiency 18.2/25 · ROCE 36.7% · Operating margin 1.3% · 76% evidence Valuation 16.0/20 · P/E 19.3× · PEG 0.39 · 65% evidence Relative strength 20.0/20 · Lead over its industry 12% · Lead over S&P 500 10.5% · 1 year 17.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.7 + 18.2 + 16 + 20 = 79.9 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Cencora, Inc.](https://www.sectoralpha.in/us/stocks/cor) COR · breaking out · Evidence leans up · 85% evidence 63.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.7/35 · Revenue 5.1% · Profit 38.4% · Operating margin change 0.2 points · 95% evidence Capital efficiency 14.9/25 · ROCE 18.3% · Operating margin 1.4% · 76% evidence Valuation 15.5/20 · P/E 21× · PEG 0.54 · 65% evidence Relative strength 13.5/20 · Lead over its industry 1.3% · Lead over S&P 500 -0.1% · 1 year -5.6% · 100% evidence · 8 of 12 weeks ahead Exact sum: 19.7 + 14.9 + 15.5 + 13.5 = 63.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 3. [Cardinal Health, Inc.](https://www.sectoralpha.in/us/stocks/cah) CAH · turning · Evidence leans up · 85% evidence 58.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.9/35 · Revenue 14.2% · Profit 9.8% · Operating margin change 0.2 points · 95% evidence Capital efficiency 15.9/25 · ROCE 24.5% · Operating margin 1.3% · 76% evidence Valuation 5.0/20 · P/E 32.5× · PEG 2.72 · 65% evidence Relative strength 16.6/20 · Lead over its industry 11.2% · Lead over S&P 500 9.8% · 1 year 24.2% · 100% evidence · 7 of 12 weeks ahead Exact sum: 20.9 + 15.9 + 5 + 16.6 = 58.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Henry Schein, Inc.](https://www.sectoralpha.in/us/stocks/hsic) HSIC · quiet · Evidence leans down · 85% evidence 41.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.6/35 · Revenue 6.5% · Profit 6% · Operating margin change 0.4 points · 95% evidence Capital efficiency 12.6/25 · ROCE 9.9% · Operating margin 5.8% · 76% evidence Valuation 7.3/20 · P/E 24× · PEG 2.33 · 65% evidence Relative strength 7.4/20 · Lead over its industry -0.6% · Lead over S&P 500 -1.8% · 1 year 14.7% · 100% evidence · 4 of 12 weeks ahead Exact sum: 14.6 + 12.6 + 7.3 + 7.4 = 41.9 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. Akso Health Group this page AHG · basing · Too little evidence to rank firmly · 51% evidence 35.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.2/35 · Revenue n/a · Profit n/a · Operating margin change 5.6 points · 26% evidence Capital efficiency 4.8/25 · ROCE -2.2% · Operating margin -37.5% · 76% evidence Valuation 9.5/20 · P/E 25.6× · PEG n/a · 15% evidence Relative strength 3.7/20 · Lead over its industry -20.9% · Lead over S&P 500 -23.3% · 1 year -22.9% · 100% evidence · 0 of 12 weeks ahead Exact sum: 17.2 + 4.8 + 9.5 + 3.7 = 35.2 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 6. EDAP TMS S.A. FOCL · quiet · Most evidence points down · 67% evidence 28.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.2/35 · Revenue 7.1% · Profit n/a · Operating margin change 8.8 points · 71% evidence Capital efficiency 3.0/25 · ROCE -71.4% · Operating margin -60.8% · 76% evidence Valuation 8.5/20 · P/E 71.3× · PEG n/a · 15% evidence Relative strength 2.7/20 · Lead over its industry -2.6% · Lead over S&P 500 -4.3% · 1 year 103.5% · 100% evidence · 0 of 12 weeks ahead Exact sum: 14.2 + 3 + 8.5 + 2.7 = 28.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. Empro Group Inc. EMPG · Too little evidence to rank firmly · 16% evidence 56.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 22.7/43.75 · Revenue n/a · Profit n/a · Operating margin change 65.6 points · 5% evidence Capital efficiency 21.6/31.25 · ROCE 39.6% · Operating margin 36.1% · 57% evidence Valuation 12.5/25 · P/E n/a · PEG n/a · 0% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 22.7 + 21.6 + 12.5 = 56.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 8. Accendra Health, Inc. ACH · Too little evidence to rank firmly · 38% evidence 36.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 13.7/43.75 · Revenue n/a · Profit n/a · Operating margin change -8.7 points · 45% evidence Capital efficiency 8.6/31.25 · ROCE 4.3% · Operating margin -1.5% · 76% evidence Valuation 14.4/25 · P/E -35.7× · PEG n/a · 15% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 13.7 + 8.6 + 14.4 = 36.7 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Jun 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Medical Distribution](https://www.sectoralpha.in/us/sectors/medical-distribution), all 8 compared on one page. ## Which companies are close to Akso Health Group in size? Akso Health Group is the 5th largest of 6 Medical Distribution companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: McKesson Corporation, Cencora, Inc., Cardinal Health, Inc. and Henry Schein, Inc. Just below it: EDAP TMS S.A. ### Medical Distribution companies close in size

1. [McKesson Corporation](https://www.sectoralpha.in/us/stocks/mck) $116.5 billion
2. [Cencora, Inc.](https://www.sectoralpha.in/us/stocks/cor) $65 billion
3. [Cardinal Health, Inc.](https://www.sectoralpha.in/us/stocks/cah) $58.6 billion
4. [Henry Schein, Inc.](https://www.sectoralpha.in/us/stocks/hsic) $9.2 billion
5. Akso Health Group $1 billion
6. [EDAP TMS S.A.](https://www.sectoralpha.in/us/stocks/focl) $189 million

[All 6 Medical Distribution companies, largest first](https://www.sectoralpha.in/us/sectors/medical-distribution#all-companies)

### Companies close in size in other industries

1. [Alphatec Holdings, Inc.](https://www.sectoralpha.in/us/stocks/atec) $1.1 billion · Medical Devices
2. [Univest Financial Corporation](https://www.sectoralpha.in/us/stocks/uvsp) $1.1 billion · Banks - Regional
3. Akso Health Group $1.1 billion
4. [BrightView Holdings, Inc.](https://www.sectoralpha.in/us/stocks/bv) $1.1 billion · Specialty Business Services
5. [Riskified Ltd.](https://www.sectoralpha.in/us/stocks/rskd) $1.1 billion · Software - Application

## What else do people ask about Akso Health Group? ### What is Akso Health Group's stock price today? Akso Health Group's stock price is $1.21, −25.3% over the past year. The whole company is worth $1.0 B on the market. In the last 52 weeks it traded between $1 to $3; today it is 26% of the way up from the low, 19.9% below its 200-day average (as of 3 November 2026). ### What were Akso Health Group's latest quarterly results? Akso Health Group reported revenue of $6.8 M and a net loss of $17.4 M for the Mar 2026 quarter. Earnings per share were −$0.02. The operating margin was −37.5%, 5.6 percentage points higher than a year earlier (as of 3 November 2026). ### What is Akso Health Group's market cap? Akso Health Group's market capitalisation is $1.0 B at a stock price of $1.21. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Akso Health Group performing? Akso Health Group's latest readings are below. Over the past 13 weeks it has done worse than the S&P 500, for 24 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Akso Health Group's stock price go up? This page does not forecast Akso Health Group's stock price. What it shows instead: the stock price is $1.21. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Akso Health Group in its business cycle? Akso Health Group's FY26 operating margin was −28.9%, against a 5-year range of −357.8% to −26.5%: the middle of its own range, neither a peak nor a low. The latest quarter was −37.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Akso Health Group story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Akso Health Group a stock worth studying right now? What the numbers show: Akso Health Group's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.